US imposes 100% tariff on imported pharmaceuticals, targeting Australia and global exporters
Consensus Summary
Donald Trump imposed a 100% tariff on patented pharmaceuticals imported into the US, effective July 31, 2025, targeting global exporters including Australia. The move, enacted under national security powers, aims to reshoring drug production to the US and address perceived unfair pricing disparities, particularly with Australiaâs Pharmaceutical Benefits Scheme (PBS), which keeps drug prices lower for Australians than Americans. Australiaâs exports to the US totaled around $US1.3 billion in 2025, with CSL, a Melbourne-based company, producing the majority of these exports. CSL has invested heavily in US manufacturingâannouncing a $US1.5 billion to $US2.2 billion expansion in Illinoisâto mitigate the tariffâs impact. The tariff applies only to patented drugs, not generics, and offers reduced rates (20%) or exemptions (0%) for companies that relocate production to the US or secure âmost favoured nationâ drug pricing deals. Countries like Japan, the EU, South Korea, and Switzerland have negotiated lower tariffs (15%), while the UK secured a 10% rate with potential future reductions. The Australian government, led by Health Minister Mark Butler, has firmly rejected pressure to alter the PBS, calling it a cornerstone of healthcare for 80 years. Opposition Leader Angus Taylor has pledged to work with the government to overturn the tariffs or secure exemptions for Australian exporters. The tariff announcement follows a Supreme Court ruling in February 2025 that invalidated Trumpâs broader âLiberation Dayâ tariffs, but this pharmaceutical tariff was enacted under different legislation and remains unaffected. CSLâs plasma-derived therapies, which treat rare diseases, may qualify for exemptions due to their critical health needs, while the company continues negotiations with the US administration to ensure market access.
â Verified by 2+ sources
Key details reported by multiple sources:
- Donald Trump signed an executive order imposing a 100% tariff on patented pharmaceuticals manufactured outside the US, effective July 31, 2025, under Section 232 of the Trade Expansion Act (NEWSCOMAU, SMH, THEAGE, ABC, GUARDIAN).
- Australia exported $US1.32 billion ($US1.3 billion) in pharmaceuticals to the US in 2025, with CSL (Melbourne-based) accounting for the bulk of these exports (NEWSCOMAU, ABC, GUARDIAN).
- The tariff applies only to patented drugs, not generic medicines (NEWSCOMAU, ABC).
- CSL has US manufacturing facilities in Illinois and North Carolina, with a $US2.2 billion (or $US1.5 billion) expansion announced in March 2025 for its Illinois factory, set to complete by 2031 (NEWSCOMAU, SMH, THEAGE, GUARDIAN).
- The US Supreme Court ruled in February 2025 that Trumpâs âLiberation Dayâ tariffs were illegal, but the pharmaceutical tariffs were enacted under different legislation and are unaffected (NEWSCOMAU, ABC, THEAGE).
- Companies moving production to the US can reduce tariffs to 20%, and those securing âmost favoured nationâ drug pricing deals can avoid tariffs entirely (NEWSCOMAU, SMH, THEAGE, GUARDIAN).
- Japan, EU, South Korea, Switzerland, and Liechtenstein have negotiated 15% tariffs, while the UK secured a 10% tariff with potential for future reductions (NEWSCOMAU, SMH, THEAGE, ABC).
- Australiaâs Pharmaceutical Benefits Scheme (PBS) subsidizes drug prices, making them cheaper for Australians than in the US, which the Trump administration has criticized (NEWSCOMAU, ABC, GUARDIAN).
- Health Minister Mark Butler stated Australia would not negotiate changes to the PBS, calling it âfundamentalâ to Australian healthcare (NEWSCOMAU, SMH, THEAGE, GUARDIAN).
- CSLâs plasma-derived therapies (used for rare autoimmune diseases and blood-clotting disorders) may qualify for tariff exemptions if they meet urgent US health needs (NEWSCOMAU, SMH, THEAGE, GUARDIAN).
- Large pharmaceutical companies have 120 days to announce re-shoring plans or pricing deals to avoid the tariff, while smaller companies have 180 days (SMH, ABC, GUARDIAN).
- Australia and the US have a 20-year-old free trade agreement covering pharmaceutical exports (NEWSCOMAU, SMH, THEAGE).
- Opposition Leader Angus Taylor (Coalition) pledged to work with the government to overturn the tariffs or secure exemptions for Australian exporters (NEWSCOMAU, SMH, THEAGE, GUARDIAN)
Points of Difference
Details reported by only one source:
- The tariff applies to patented products only, not generic medicines, and is invoked under national security powers (Section 232) to address âthreatened impairment of national securityâ from pharmaceutical imports (not covered by Supreme Court ruling).
- A White House official stated pharmaceutical companies could negotiate deals with the White House to lower US prices and avoid tariffs, citing AstraZeneca as an example of a company that has already struck such deals.
- The tariff on steel components was adjusted: products with less than 15% steel will have zero additional tariffs, while those exceeding 15% steel will face a 25% tariff on the total value.
- The tariff announcement was timed to mark one year since Trumpâs âLiberation Dayâ tariffs (February 2025), which were later struck down by the Supreme Court.
- The Commerce Department has discretion to grant exemptions to companies like CSL, which must submit their re-shoring plans for review.
- The UKâs tariff deal is âeven lowerâ than the 10% rate mentioned in other sources, with potential for future reductions to zero.
- A senior administration official stated that too many drugs âdriven by research and development in the USâ are now produced abroad, making the US dependent on foreign countries.
- Trump previously suggested the tariff could be as high as 200%, but it was ultimately set at 100%.
- CSLâs social media post in September 2024 suggested the tariff would take effect in October 2024, but it was delayed until July 2025.
- No unique details beyond those already covered in other sources; SBS headline is a summary of broader concerns.
- The headline and content are nearly identical to SMH and GUARDIAN, with no additional unique details.
- Communications Minister Anika Wells stated the Australian PBS is âworld leadingâ and ânot for sale,â emphasizing its high value to Australians.
- The Guardian noted that American consumers pay far more for prescription medicines than Australians, a key frustration for Trump.
Contradictions
Conflicting information between sources:
- NEWSCOMAU states the tariff applies to patented products only, while ABC does not explicitly exclude generic medicines from the tariff language but focuses on patented drugsâno direct contradiction but ABCâs phrasing is less precise.
- SMH and THEAGE mention the UKâs tariff rate as âeven lowerâ than 10%, while NEWSCOMAU and ABC state the UK has a 10% tariff with room to go to zeroâSMH/THEAGE imply a lower rate than 10% currently, but this is not quantified.
- NEWSCOMAU reports CSLâs Illinois factory expansion as $US2.2 billion, while SMH, THEAGE, and GUARDIAN report $US1.5 billionâthis discrepancy may be due to differing sources or reporting of the same announcement.
- ABC states Trump previously suggested the tariff could be as high as 200%, but NEWSCOMAU and SMH do not mention this 200% figureâonly ABC highlights this earlier threat.
- NEWSCOMAU and SMH mention that Australia has a long-standing free trade agreement with the US for 20 years, but ABC does not specify the durationâonly that it exists.
Source Articles
Trump slaps huge tariff on medicines
US President Donald Trump has followed through on another tariff threat, putting a 100 per cent levy on a major Australian export....
Trump imposes 100 per cent tariff on Australian drugs â but with caveats
Australiaâs largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Breaking: Trump puts 100pc tariff on some pharmaceuticals
The US president's latest order shows he remains committed to his aggressive tariff regime despite February's Supreme Court ruling that invalidated his centrepiece "liberation day" tariffs....
What Trump's 100 per cent pharmaceutical tariff means for Australia
Australia exported nearly two billion dollars worth of pharmaceuticals to the US last year....
Trump imposes 100 per cent tariff on Australian drugs â but with caveats
Australiaâs largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Australia says it wonât raise drug prices after Trumpâs 100% tariff on pharmaceuticals imported into US
Health minister Mark Butler says federal government is ânot negotiatingâ when it comes to removing price protections on common medications Get our breaking news email , free app or daily news podcast ...